Yet, laser treatment may permanently damage the retina, and anti-VEGF therapies have limitations including recurrence, dosing, and long-term safety concerns [18,19], hence necessitating the need for additional ROP research in experimental models. The gene discussed is VEGFA; the disease is retinopathy of prematurity.